Clinical Trial

Observational Study: Hetrombopag for Platelet Recovery in Haploidentical HSCT

Completed
View on ClinicalTrials.gov →
Summary
The objective of this observational study is to investigate the long-term effects of Hetrombopag in promoting platelet engraftment during haploidentical hematopoietic stem cell transplantation (HSCT) in children with thalassemia, with a specific focus on a 28-day time window post-transplantation. The core question to be addressed is: Is Hetrombopag safe and effective for platelet engraftment in children with thalassemia undergoing haploidentical HSCT within a 28-day post-transplant period? Subjects who received Hetrombopag as part of routine care for haploidentical HSCT in children with thalassemia will be required to complete a 28-day online survey on platelet engraftment outcomes.
Protocol Amendment History 1 change
critical Trial status changed: Enrolling by Invitation → Completed 2026-07-29
Trial Details
NCT Number NCT07003269
Lead Sponsor Haikou Affiliated Hospital of Central South University Xiangya School of Medicine
Conditions Thalassemia in Children
Enrollment 30 participants
Start Date 2024-09-01
Primary Completion 2026-04-30 (estimated)
Study Completion 2026-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-28